

# FY22 Results Announcement

29 March 2022

## **Vikesh Ramsunder** CEO and Managing Director






### **Overview**

- Review of the year
- Financial Performance
- Business update
- Strategic focus
- Outlook

## **Review of the Year**

- Trading performance
- Operational performance
- ERP implementation
- Distribution Centre investment program
- Final Dividend of 1.0 cent per share fully franked



## **Jeff Sells** CFO



## **Financial Performance**

Statutory Results (\$'m)	% Change	FY22	FY21*
Net Sales	1.3%	3,446.2	3,400.40
Gross Profit	-5.1%	227.1	239.2
Other Revenue	-18.7%	112.5	138.4
Operating Costs	-0.2%	(309.6)	(309.0)
EBITDA	-56.3%	30.0	68.6
Depreciation and Amortisation	-3.1%	(27.7)	(28.6)
EBIT	-94.2%	2.3	40.0
Net Interest	7.4%	(10.6)	(11.5)
Tax benefit	-88.0%	2.0	16.50
Net controlling interests	39.4%	(0.9)	(1.5)
NPAT	-116.6%	(7.2)	43.5

\* FY 21 restated due to SaaS accounting policy change

#### Sales Revenue up 1.3% to \$3.45bn

- Benefited from:
  - Overall strong sales growth in 1H22
  - Retail brands LFL sales up 6.4% for the full year
  - CW sales up by 13% reflecting full year run rate
  - Hospital sales up 5.6%
  - High volume sales of Rapid Antigen Tests in January 2022
- Impacted by:
  - ERP implementation lost sales from existing customers and stalled growth from new customers
  - Lower PPE and Export sales compared to prior year

#### Gross Profit down 5.1% to \$227m

- Reflects a return to a more normal product sales mix following a spike in PPE sales in FY21
- Higher inventory adjustments by \$6.0m due to ERP implementation and DC transfer

#### Other Revenue - Down 18.8% to \$112m

- FY21 included \$29.4m profit on sale of property
- Excluding this, Other Revenue was up 4.7% from a recovery in commissions and promotional revenue

### **Total Operating Expenses – up 0.2%**

### Warehouse and Delivery: Up 5.3% to \$154.9m

- Short term increase in labour and logistics costs to support the business through ERP implementation
- Dual operating and transitional impact on productivity relating to the move from Rowville DC to Truganina DC
- \$4.2m one-off people and warehouse cost due to closure of Rowville DC


### Sales and Marketing: Down 8.5% to \$61.7m

- \$4.1m savings in people and contractor cost due to change in organisational structure
- Efficiency gains in marketing programs of \$1.2m partially offset by higher doubtful debt expense


### Administration: Down 1.5% to \$93.0m

- Savings in people cost and consultant costs
- Includes \$31.8 million SaaS adjustment in FY22, with FY21 re-stated to reflect new SaaS standard. FY21 amount was \$25.6 million
- Increased software and managed service spend because of new ERP

## **Cash Management and Debt**



## **Cash Conversion Cycle**



Cash conversion cycle*	<u>Jan-22</u>	<u>Jan-21</u>
Trade Debtors	343,315	310,525
Inventory	321,640	349,138
Trade Creditors	(352,273)	(365,469)
Working Cap \$'000	312,682	294,194
Days sales outstanding (DSO)	36	33
Days inventory outstanding (DIO)	36	40
Days payables outstanding (DPO)	(40)	(42)
CCC Days	33	31

- Cash conversion cycle increase by 2 days to 33 days
- Increase in Debtors balance due to Rapid Antigen tests in Jan 22
- Improvement required in the DPO and DIO spread

## **Capital Expenditure and ROIC**

### Сарех

- Capital investment program near completion
- Total spend close to \$390m over the last 5 years
- Expect circa \$40-\$45m capex in FY23 to complete Truganina extension, construct Hobart DC, and finalise IT projects
- Return to normal capex of circa \$5m \$10m from FY24

### ROIC

- At the low point of the cycle given investment program and the current capacity underutilisation
- ROIC is 0.4% adopting unadjusted Statutory EBIT



FY22 (A)

FY 23 (F)

FY 24 (F)

FY21 (A)

120

100

80

60

40

20

FY18 (A)

FY19 (A)

FY20 (A)




## **ERP Implementation**

- ERP implementation impacted our customers and our business
- Good progress has been made on identifying and resolving system issues
- Focus is on process improvements to enhance customer service
- Targeting 30 April 2022 for full stabilisation
- Targeting January 2023 for full optimisation
- Rebuild customer confidence and trust



### Wholesale

- Total revenue of \$3.4 billion
- Core business capability with over 220 million medicines distributed to community and hospital pharmacies
- Pharmacy Wholesale market share currently circa 19.9% impacted by ERP implementation
- Focus on stabilisation and optimisation




## **Community Pharmacy**

- Over 530 pharmacies operating under one of our pharmacy brands
- Sales at the pharmacy level circa 17%\* of consumer spend in pharmacy
- FY22 Sales to our pharmacy brands down 2%
- Almost 650,000 Covid-19 vaccines administered across the network since June
- Private Label range over 500 products
- Focus on improving consumer value proposition




## **Contract Logistics**

- Growth of 15.8% over the last 12 months
- Currently managing 30,000 pallets of medicines for customers (nationally)
- Servicing 11 clients
- Truganina DC expansion to add 20,000 pallet capacity



## **MPS CONNECT**



- Growth in MPS sales despite Covid-19 restrictions
- 20% of market share of packing services to Residential Aged Care (RAC) patients
- Business growth opportunity reach and market penetration
- In FY22 MPS launched market leading integrated software solutions to RAC that opens access to a broader market
- Improve operational efficiencies

## **Outlook - moving the business forward**

1. No FY23 guidance, but expect to return to profit

### 2. Immediate focus

- ERP stabilisation and optimisation
- Truganina DC, Victoria enhance operational performance

### 3. Short term focus

- Get the basics right obsessed with servicing the customer
- Simplify the business ensure accountability and execution
- Improve decision making clear and transparent reporting

### 4. Long term focus

• Provide market update on strategy at half year results

Focus on leveraging world class assets to enable a competitive advantage that can deliver long term sustainable growth

# Thank you

### **Appendix – Reconciliation to Underlying guidance**

Reconciliation or Reported to Underlying EBITDA	<u>Jan-22</u>
Reported EBITDA	30,004
Add Back One-Off Adjustments	
Restructuring, transformation, and dual operating costs	30,078
SaaS adjustment	31,811
Other	255
Underlying EBITDA	92,148

### **Important Notice**

The information contained in this presentation about Sigma Healthcare Limited and its subsidiaries (Sigma) is designed to provide:

- an overview of the financial and operational highlights for Sigma for the full year period ending 31 January 2022; and
- a high level overview of aspects of the operations of Sigma, including comments about Sigma's expectations of the outlook for FY2022 and future years, as at 29 March 2022.

This presentation contains forward-looking statements relating to operations of Sigma that are based on management's own current expectations, estimates and projections about matters relevant to Sigma's future financial performance.

Any forward-looking statements, assumptions, projections, estimates, and outcomes contained in this presentation should not be relied upon as a representation or warranty, express or implied by Sigma. They are not an assurance or guarantee of future performance nor should be taken to be, and involve known and unknown risks, uncertainties and other factors which are beyond the control of Sigma in relation to the future business performance or results of Sigma or the likelihood that the assumptions, estimates or outcomes will be achieved.

While Sigma, its officers and management have made every effort to ensure the accuracy of the information in this presentation, this presentation is provided for information only. Neither Sigma, its directors, officers, agents, employees or advisors make any representation, or given any warranty, express or implied, as to the fairness, accuracy, completeness or correctness of the information, forward-looking statements, opinions, estimates, projections, outcomes and conclusions contained in this presentation. Accordingly, to the maximum extent permitted by law, Sigma, its directors, officers, agents, employees and advisors exclude and disclaim any liability, whether direct or indirect, in respect of the accuracy or completeness of the information or any other opinions contained in this presentation or errors, omissions, statements or for any loss, howsoever arising, from anything done in reliance or the use of this presentation.

Sigma assumes no obligation to update or revise any forward-looking statements. Nothing in this presentation constitutes investment advice and this presentation shall not constitute an offer, invitation, solicitation or other recommendation to sell or buy any securities or otherwise engage in any investment activity in Sigma Healthcare Limited. Investors should make their own enquiries and seek their own professional advice (including financial and legal advice) before dealing in securities of Sigma Healthcare Limited.